Financials in USD. Standardized financial statements.
A compact view of how Organicell Regenerative Medicine, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $5.20M | $4.62M | $4.56M | $6.49M | $5.60M | $3.06M | $1.70M | $964,530 | $569,845 | $184,881 |
| Revenue Growth? | +12.5% | +1.4% | -29.8% | +16.0% | +83.2% | +79.5% | +76.5% | +69.3% | +208.2% | 0.0% |
| Cost of Revenue? | $931,000 | $844,000 | $507,629 | $753,534 | $547,881 | $398,606 | $300,837 | $209,298 | $160,626 | $94,402 |
| Gross Profit? | $4.27M | $3.78M | $4.05M | $5.74M | $5.05M | $2.66M | $1.40M | $755,232 | $409,219 | $90,479 |
| Gross Margin? | +82.1% | +81.7% | +88.9% | +88.4% | +90.2% | +87.0% | +82.3% | +78.3% | +71.8% | +48.9% |
| Operating Expenses? | $9.65M | $9.10M | $10.82M | $14.58M | $17.79M | $15.10M | $3.18M | $4.25M | $9.05M | $1.13M |
| Operating Income? | -$5.39M | -$5.32M | -$6.77M | -$8.84M | -$12.74M | -$12.44M | -$1.78M | -$3.49M | -$8.64M | -$1.04M |
| EBITDA? | -$5.39M | -$5.32M | -$6.07M | -$8.17M | -$12.67M | -$12.37M | -$1.68M | -$3.46M | -$8.61M | -$1.04M |
| Income Before Tax | -$5.52M | -$4.71M | -$6.99M | -$8.90M | -$12.76M | -$12.58M | -$1.74M | -$3.43M | -$9.11M | -$1.06M |
| Income Tax Expense | $0 | $0 | $0 | $53,597 | $63,411 | $210,460 | $130,413 | -$234,862 | -$236,358 | $197,155 |
| Net Income? | -$5.52M | -$4.71M | -$6.99M | -$8.95M | -$12.82M | -$12.79M | -$1.87M | -$3.46M | -$8.97M | -$1.25M |
| EPS? | $-0.86 | $-0.74 | $-0.99 | $-1.57 | $-2.42 | $-3.81 | $-0.80 | $-2.55 | $-16.52 | $-2.50 |
| Diluted EPS? | $-0.86 | $-0.74 | $-0.99 | $-1.57 | $-2.42 | $-3.81 | $-0.80 | $-2.55 | $-16.52 | $-2.50 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality